## Management of Hyperthyroidism in Pregnancy ### Clinical Context: Post-Radioiodine Graves' Disease in Pregnancy This patient has: - **Post-radioiodine hypothyroidism** (most likely, given prior ablation) - **Elevated free T4** in the second trimester - **Pregnancy at 24 weeks** (critical period for fetal thyroid development) - **No current antithyroid medication** **Key Point:** Hyperthyroidism in pregnancy carries significant risks: miscarriage, preterm labor, intrauterine growth restriction, and fetal thyrotoxicosis. Treatment is mandatory, but drug choice is critical. ### Why PTU Is the Correct Choice ```mermaid flowchart TD A[Hyperthyroidism in Pregnancy]:::outcome --> B{Trimester?}:::decision B -->|First trimester| C[PTU preferred]:::action B -->|Second/Third trimester| D{Stable?}:::decision D -->|Yes, mild| E[PTU or PTU + levothyroxine]:::action D -->|Severe/uncontrolled| F[PTU monotherapy]:::action C --> G[Avoid methimazole: teratogenic risk]:::urgent E --> H[Monitor TSH, free T4 q4-6 weeks]:::action F --> I[Target: TSH 0.5-2.0 mIU/L, free T4 in upper-normal range]:::action ``` ### Antithyroid Drug Comparison in Pregnancy | Feature | PTU | Methimazole | | --- | --- | --- | | **Mechanism** | Blocks T4 and T3 synthesis; inhibits peripheral conversion of T4→T3 | Blocks T4 and T3 synthesis only | | **Placental transfer** | Minimal (protein-bound) | Crosses placenta readily | | **Teratogenicity** | None established | Methimazole embryopathy (rare but documented) | | **Fetal/neonatal risk** | Low | Aplasia cutis, esophageal atresia, choanal atresia | | **Hepatotoxicity** | Rare but serious (0.1–0.3%) | Very rare | | **Agranulocytosis** | 0.3–0.5% | 0.3–0.5% | | **Preferred in pregnancy** | **Yes (all trimesters)** | Avoid (especially 1st trimester) | **High-Yield:** PTU is the drug of choice for hyperthyroidism in pregnancy because: 1. Minimal placental transfer (highly protein-bound) 2. Blocks peripheral conversion of T4 → T3, reducing fetal thyroid hormone exposure 3. No established teratogenic risk 4. Methimazole carries documented teratogenic risk (methimazole embryopathy) ### Dosing and Monitoring **Initial PTU dose:** 100 mg TDS (300 mg/day), titrated based on response **Target TSH:** 0.5–2.0 mIU/L (slightly higher than non-pregnant range to avoid overtreatment and fetal hypothyroidism) **Target free T4:** Upper half of the normal range (to balance maternal control and fetal safety) **Monitoring:** TSH and free T4 every 4–6 weeks (more frequent than non-pregnant patients due to physiologic changes in thyroid-binding proteins) **Clinical Pearl:** Pregnancy increases TBG (thyroxine-binding globulin) by ~1.5-fold, which can lower free T4 and falsely suggest worsening hyperthyroidism. Always interpret free T4 in the context of TSH and clinical symptoms. ### Why Other Options Are Incorrect **Propranolol alone (Option A):** - Beta-blockers provide symptom relief (tachycardia, tremor, anxiety) but do NOT treat the underlying hyperthyroidism - They do not reduce thyroid hormone synthesis or release - Propranolol has a minor advantage of inhibiting peripheral T4→T3 conversion, but this is insufficient monotherapy - Free T4 remains elevated, risking fetal thyrotoxicosis **Deferring treatment until third trimester (Option C):** - Dangerous and unethical; hyperthyroidism in the second trimester increases miscarriage risk - Fetal thyroid development is active in the second trimester; maternal thyroid hormones cross the placenta and are critical for fetal CNS development - Delaying treatment exposes the fetus to prolonged maternal hyperthyroidism **Thyroidectomy (Option D):** - Thyroidectomy is reserved for: - Severe hyperthyroidism uncontrolled by PTU (rare) - Adverse drug reactions (agranulocytosis, hepatitis) - Patient preference for definitive therapy - It is NOT indicated as first-line therapy in pregnancy - Surgery in the second trimester carries anesthetic and obstetric risks - This patient is not in thyroid storm; medical management is appropriate ### Management Summary 1. **Start PTU 100 mg TDS immediately** (first-line antithyroid agent in pregnancy) 2. Recheck TSH and free T4 in 4–6 weeks 3. Titrate PTU dose to target TSH 0.5–2.0 mIU/L and free T4 in upper-normal range 4. Consider adding levothyroxine if PTU causes hypothyroidism (block-and-replace strategy is less commonly used in pregnancy due to PTU's dual action) 5. Continue PTU throughout pregnancy and postpartum (PTU is safe in breastfeeding) 6. Plan for neonatal screening (cord blood TSH) given maternal hyperthyroidism history [cite:Harrison 21e Ch 405, ACOG Guidelines on Thyroid Disease in Pregnancy]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.